Cosmecca Korea Co. Ltd (241710) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Cosmecca Korea Co. Ltd stock KRW 88,567, price KRW 86,100, upside +2.9%, quality 53 out of 100. Rating: fairly valued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range 6,478 KRW – 153,900 KRW · fair‑value band 64,648 KRW – 111,685 KRW · the 86,100 KRW price screens below the 88,567 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Cosmecca Korea Co. in your weekly email
Every Wednesday you see whether Cosmecca Korea Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Cosmecca Korea Co., Ltd. engages in the research and development, manufacture, and sale of skincare products in South Korea and internationally.
Show moreShow less
It offers skincare products, including lotion/toner, cream, essence, cleansers, Korean herbal products, mask sheet, scalp care, home scents, body and bath, exfoliators, and treatment products, as well as products for men, babies, and children; functional skincare products, which includes brightening, wrinkle and fine line, UV blocks/sunscreen, tanning, multi-functional, hair and body, and acne care products; and makeup products, such as BB and CC cream, skin cover balms, makeup base, foundation, concealer, lipstick, mascara, eyeliner, eyeshadow, blush/highlighter, and powders.
The company was incorporated in 1999 and is headquartered in Eumseong-eup, South Korea.
Stock analysis
Cosmecca Korea Co. Ltd (241710) currently trades at 86,100 KRW, while our model-based Fair Value estimate is 88,567 KRW, so the stock looks roughly fairly valued today (gap 2.8%).
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 98,338 KRW per share, and 5 of the 16 models we run sit above the 86,100 KRW price.
Bear case: the Economic Profit group reads lowest at 47,501 KRW, and 11 of the 16 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 64,648 KRW (bear) to 111,685 KRW (bull), the price of 86,100 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 53/100 (solid quality), in the Consumer Defensive sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Cosmecca Korea Co. Ltd reported revenue of 641B KRW in FY2025 versus 396B KRW in FY2021, a compound +12.8%/yr. Reported net income was 45.4B KRW in FY2025, compounding +50.3%/yr from FY2021.
Key figures
Market cap 912B KRW (≈ $675M) Small · P/E ratio 14.4 · P/S ratio 1.50 · EPS (TTM) 5,976 KRW · Dividend yield 0.4% · Net margin 8.3% · Return on equity 24.8% · Return on assets (EBIT) 8.7% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 59 out of 100 (low confidence).
What moves the price
The share trades about 44% below its 52-week high and 35% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −26% fair-value upside, at 3%, 241710 screens cheaper than that median.
Fair Value models
Bear64,648 KRWFair Value 88,567 KRWBull111,685 KRW
Price 86,100 KRW · Upside +2.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (4,807 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+22.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.6%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.3%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
≈ +77.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year≈ +76.9%
Dividend (yield on the price)0.4%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.base effect: 56.3% / 14.7%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.3% → 13%
2025 sits 104% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
⚠ Base effect: the rate starts in the earnings trough around 2020 (starting value 456 per share, median 930 in 2016 to 2018). It measures the recovery from the trough, not lasting growth.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Household & Personal Products · 229 stocks
Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score53 · Below median
Fair Value upside+2.9% · Below median
Profitability
Return on equity (12 months)24.8% · Top 25%
Return on assets9.2% · Top 25%
Net margin (12 months)10.5% · Above median
Operating margin (12 months)13.1% · Above median
Growth and dividend
Revenue growth (quarter YoY)39.8% · Top 25%
Dividend yield (12 months)0.4% · Bottom 25%
Balance sheet
Debt / equity0.12× · Above median
Valuation Multiplesvs Household & Personal Products median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Cosmecca Korea Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/241710
Frequently asked questions
Is Cosmecca Korea Co. Ltd (241710) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of 88,567 KRW versus a price of 86,100 KRW, about +3% upside (fairly valued).
What is the fair value of 241710?
Our model-based fair value for Cosmecca Korea Co. Ltd is 88,567 KRW (as of Nov 6, 2026), built from audited fundamentals. The current price: 86,100 KRW.
What is the quality score of 241710?
Cosmecca Korea Co. Ltd has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cosmecca Korea Co. Ltd (241710)?
Our model-based price target is the fair value of 88,567 KRW (as of Nov 6, 2026) from 16 valuation models. Cautious scenario 64,648 KRW, optimistic scenario 111,685 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Cosmecca Korea Co. Ltd stock forecast for 2026?
Our models put fair value at 88,567 KRW, about +3% upside versus a price of 86,100 KRW (fairly valued). Cautious scenario 64,648 KRW, optimistic scenario 111,685 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Cosmecca Korea Co. Ltd (241710)?
Cosmecca Korea Co. Ltd reported trailing-twelve-month revenue of about 772B KRW (latest available figure, as of Nov 6, 2026).
Does Cosmecca Korea Co. Ltd pay a dividend?
Cosmecca Korea Co. Ltd currently shows a dividend yield of 0.43% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of Cosmecca Korea Co. Ltd (241710) and when is the ex-dividend date?
Cosmecca Korea Co. Ltd pays a dividend of 370.00 KRW per share a year, a dividend yield of 0.4%. The last ex-dividend date was Dec 29, 2025. The payout ratio is 6.2% of earnings. Our assessment: Token dividend. At a yield of 0.4% the dividend is symbolic. On paper it is not fully covered by earnings or free cash flow, but at this size that hardly matters: even scrapping it entirely would cost less than 0.4% a year, and coverage ratios on amounts this small swing with ordinary working-capital movements. Judge this company on its business, not on its dividend.
What is the intrinsic value of Cosmecca Korea Co. Ltd (241710)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cosmecca Korea Co. Ltd it is 88,567 KRW per share (as of Nov 6, 2026), against a price of 86,100 KRW. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Cosmecca Korea Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 6, 2026, 241710 trades below its calculated fair value: price 86,100 KRW, fair value 88,567 KRW, a gap of about +3% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 241710?
No. The price is what the market pays today (86,100 KRW); the fair value is what the company's own numbers justify (88,567 KRW). For Cosmecca Korea Co. Ltd the two are 2,467 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Cosmecca Korea Co. Ltd worth?
The market values Cosmecca Korea Co. Ltd at about 912B KRW (market capitalisation, as of Nov 6, 2026). Per share that is 86,100 KRW; our models calculate a fair value of 88,567 KRW per share.
What do the bullish and bearish scenarios say about 241710?
Our models span a range for Cosmecca Korea Co. Ltd: cautious scenario 64,648 KRW, base 88,567 KRW, optimistic 111,685 KRW per share (as of Nov 6, 2026, price 86,100 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 241710?
Cosmecca Korea Co. Ltd trades at a price-to-earnings ratio of 14.4 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 88,567 KRW is built from several models across several years. Median P/E at fiscal year-end, 8 fiscal years (2018 to 2025), reported earnings: 21.1. Other multiples: P/B 3.6, P/S 1.5, EV/EBITDA 9.5.
How solid is the balance sheet of Cosmecca Korea Co. Ltd (241710)?
Balance-sheet figures for Cosmecca Korea Co. Ltd (as of Nov 6, 2026): return on equity 24.8%, debt of 0.12 per unit of equity. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is 241710 from its 52-week high?
Cosmecca Korea Co. Ltd trades at 86,100 KRW, about 44% below its 52-week high of 153,900 KRW and 35% above the low of 63,900 KRW (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 88,567 KRW is for.
Which stocks are comparable to Cosmecca Korea Co. Ltd?
From the same area (Consumer Defensive) we also value Colgate-Palmolive Company, Hindustan Unilever Limited, The Estée Lauder Companies Inc, Henkel AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cosmecca Korea Co. Ltd stock attractive at the current price?
The data as of Nov 6, 2026: price 86,100 KRW, calculated fair value 88,567 KRW (+3%), Quality Score 53/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 241710 calculated?
We run Cosmecca Korea Co. Ltd through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 88,567 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Cosmecca Korea Co. Ltd currently trades 3% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cosmecca Korea Co. Ltd (241710)?
The closing price on Nov 9, 2026 was 86,100 KRW. Our model-based fair value is 88,567 KRW, about +3% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cosmecca Korea Co. Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Cosmecca Korea Co. Ltd
How large is the market capitalisation of Cosmecca Korea Co. Ltd (241710)?
The market capitalisation of Cosmecca Korea Co. Ltd is 912B KRW (≈ $675M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cosmecca Korea Co. Ltd (241710)?
The price-to-sales ratio of Cosmecca Korea Co. Ltd is 1.50 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Cosmecca Korea Co. Ltd (241710)?
Earnings per share at Cosmecca Korea Co. Ltd are 5,976 KRW (price ÷ EPS = P/E 14.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Cosmecca Korea Co. Ltd (241710)?
The dividend yield of Cosmecca Korea Co. Ltd is 0.4% (payout 6.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Cosmecca Korea Co. Ltd (241710)?
The net margin of Cosmecca Korea Co. Ltd is 8.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Cosmecca Korea Co. Ltd (241710)?
The return on equity (ROE) of Cosmecca Korea Co. Ltd is 24.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cosmecca Korea Co. Ltd (241710)?
On an EBIT basis the return on assets of Cosmecca Korea Co. Ltd is 8.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cosmecca Korea Co. Ltd (241710)?
The operating margin of Cosmecca Korea Co. Ltd is 13.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cosmecca Korea Co. Ltd (241710)?
Revenue at Cosmecca Korea Co. Ltd is growing +39.8% versus a year earlier (3y avg +17.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Cosmecca Korea Co. Ltd (241710)?
Earnings per share at Cosmecca Korea Co. Ltd are growing +93.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Cosmecca Korea Co. Ltd (241710) generate?
The free cash flow of Cosmecca Korea Co. Ltd is −6.4B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Cosmecca Korea Co. Ltd (241710) carry?
The net debt of Cosmecca Korea Co. Ltd is 96.6B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Cosmecca Korea Co. Ltd in the live analysis
One click puts Cosmecca Korea Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 6, 2026